Generic versions of semaglutide are arriving at pharmacies across Canada this week [2].
The launch provides a more affordable alternative to brand-name Ozempic for adults managing type 2 diabetes. By introducing competition, these generics aim to reduce the financial burden on patients while adhering to Health Canada's safety and efficacy standards [1].
Two generic versions of the medication are expected to start arriving in pharmacies during the week of May 20, 2026 [2]. Some pharmacists said they were already stocking their shelves prior to the official wide-scale arrival [3]. To facilitate the transition, digital prescriptions for the generic versions became available to eligible Canadians on Thursday, May 16, 2026 [4].
The cost of the generic medication is significantly lower than the brand-name version. Generic semaglutide will be sold at approximately 30% of the brand price [2]. For example, a generic pen may cost $30 compared to $100 for the brand-name Ozempic [2].
Apotex and other Canadian drug makers are manufacturing the generic semaglutide [1]. The medication uses the same active ingredient as the brand-name drug to treat type 2 diabetes [1].
Patients seeking the lower-cost alternative can consult their healthcare providers to transition their prescriptions. The availability of these generics follows a period of high demand and significant cost for the brand-name versions of the drug [1].
“Generic semaglutide will be sold at approximately 30% of the brand price.”
The introduction of generic semaglutide represents a shift in the accessibility of GLP-1 receptor agonists in Canada. By reducing the price point to roughly one-third of the brand-name cost, the market is likely to see an increase in patient adherence and a decrease in out-of-pocket spending for chronic diabetes management.
